UBS Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $39.4M | Buy |
124,674
+20,094
| +19% | +$4.73M | 0.01% | 1986 |
|
|
2026
Q1 | $20.9M | Sell |
104,580
-38,487
| -27% | -$7.61M | ﹤0.01% | 2530 |
|
|
2025
Q4 | $27M | Buy |
143,067
+31,081
| +28% | +$5.97M | ﹤0.01% | 2293 |
|
|
2025
Q3 | $19.8M | Buy |
111,986
+78,476
| +234% | +$11.7M | ﹤0.01% | 2577 |
|
|
2025
Q2 | $3.81M | Buy |
33,510
+3,074
| +10% | +$329K | ﹤0.01% | 4152 |
|
|
2025
Q1 | $3.2M | Buy |
30,436
+3,331
| +12% | +$377K | ﹤0.01% | 4250 |
|
|
2024
Q4 | $2.9M | Buy |
27,105
+15,608
| +136% | +$1.76M | ﹤0.01% | 4357 |
|
|
2024
Q3 | $1.15M | Sell |
11,497
-27,289
| -70% | -$2.75M | ﹤0.01% | 4535 |
|
|
2024
Q2 | $3.27M | Buy |
38,786
+5,723
| +17% | +$455K | ﹤0.01% | 3263 |
|
|
2024
Q1 | $2.42M | Buy |
33,063
+14,036
| +74% | +$1.03M | ﹤0.01% | 3758 |
|
|
2023
Q4 | $1.36M | Buy |
19,027
+12,111
| +175% | +$715K | ﹤0.01% | 4215 |
|
|
2023
Q3 | $414K | Sell |
6,916
-1,159
| -14% | -$76.3K | ﹤0.01% | 4802 |
|
|
2023
Q2 | $582K | Buy |
8,075
+6,894
| +584% | +$517K | ﹤0.01% | 4694 |
|
|
2023
Q1 | $86.9K | Sell |
1,181
-479
| -29% | -$34K | ﹤0.01% | 6021 |
|
|
2022
Q4 | $111K | Buy |
1,660
+1,083
| +188% | +$70.4K | ﹤0.01% | 6005 |
|
|
2022
Q3 | $31K | Sell |
577
-497
| -46% | -$29.2K | ﹤0.01% | 6834 |
|
|
2022
Q2 | $60K | Sell |
1,074
-49,074
| -98% | -$2.78M | ﹤0.01% | 5779 |
|
|
2022
Q1 | $3.52M | Buy |
50,148
+7,079
| +16% | +$514K | ﹤0.01% | 2896 |
|
|
2021
Q4 | $4.15M | Sell |
43,069
-119
| -0.3% | -$11K | ﹤0.01% | 3025 |
|
|
2021
Q3 | $3.75M | Buy |
43,188
+27,762
| +180% | +$2.15M | ﹤0.01% | 2973 |
|
|
2021
Q2 | $1.26M | Buy |
15,426
+9,408
| +156% | +$783K | ﹤0.01% | 3977 |
|
|
2021
Q1 | $573K | Sell |
6,018
-2,351
| -28% | -$222K | ﹤0.01% | 4767 |
|
|
2020
Q4 | $519K | Buy |
8,369
+636
| +8% | +$36.3K | ﹤0.01% | 4576 |
|
|
2020
Q3 | $460K | Sell |
7,733
-4,416
| -36% | -$301K | ﹤0.01% | 4261 |
|
|
2020
Q2 | $848K | Buy |
12,149
+5,195
| +75% | +$329K | ﹤0.01% | 3652 |
|
|
2020
Q1 | $315K | Sell |
6,954
-13,949
| -67% | -$791K | ﹤0.01% | 4357 |
|
|
2019
Q4 | $1.36M | Sell |
20,903
-59,170
| -74% | -$3.95M | ﹤0.01% | 3926 |
|
|
2019
Q3 | $4.97M | Buy |
80,073
+62,127
| +346% | +$3.9M | ﹤0.01% | 2388 |
|
|
2019
Q2 | $1.28M | Sell |
17,946
-38,723
| -68% | -$2.85M | ﹤0.01% | 3547 |
|
|
2019
Q1 | $4.44M | Sell |
56,669
-17,723
| -24% | -$1.34M | ﹤0.01% | 2301 |
|
|
2018
Q4 | $6.3M | Buy |
74,392
+12,697
| +21% | +$1.35M | ﹤0.01% | 1959 |
|
|
2018
Q3 | $10.6M | Buy |
61,695
+30,295
| +96% | +$4.57M | ﹤0.01% | 1739 |
|
|
2018
Q2 | $4.06M | Sell |
31,400
-68,233
| -68% | -$7.61M | ﹤0.01% | 2531 |
|
|
2018
Q1 | $10.3M | Buy |
99,633
+82,019
| +466% | +$8.11M | ﹤0.01% | 1656 |
|
|
2017
Q4 | $1.5M | Sell |
17,614
-25,989
| -60% | -$2.25M | ﹤0.01% | 3436 |
|
|
2017
Q3 | $3.7M | Sell |
43,603
-18,977
| -30% | -$1.5M | ﹤0.01% | 2516 |
|
|
2017
Q2 | $4.74M | Buy |
62,580
+32,474
| +108% | +$2.27M | ﹤0.01% | 2192 |
|
|
2017
Q1 | $1.99M | Sell |
30,106
-60,502
| -67% | -$3.98M | ﹤0.01% | 2943 |
|
|
2016
Q4 | $5.74M | Buy |
90,608
+44,823
| +98% | +$2.83M | ﹤0.01% | 1968 |
|
|
2016
Q3 | $2.92M | Sell |
45,785
-29,040
| -39% | -$2.13M | ﹤0.01% | 2499 |
|
|
2016
Q2 | $5.57M | Buy |
74,825
+55,400
| +285% | +$4.11M | ﹤0.01% | 1855 |
|
|
2016
Q1 | $1.3M | Sell |
19,425
-87,755
| -82% | -$5.33M | ﹤0.01% | 3041 |
|
|
2015
Q4 | $7.25M | Buy |
107,180
+55,022
| +105% | +$3.4M | ﹤0.01% | 1662 |
|
|
2015
Q3 | $2.79M | Buy |
52,158
+12,001
| +30% | +$728K | ﹤0.01% | 2450 |
|
|
2015
Q2 | $2.53M | Buy |
40,157
+3,211
| +9% | +$175K | ﹤0.01% | 2749 |
|
|
2015
Q1 | $1.78M | Buy |
36,946
+23,460
| +174% | +$899K | ﹤0.01% | 3043 |
|
|
2014
Q4 | $448K | Buy |
+13,486
| New | +$439K | ﹤0.01% | 4303 |
|
Other funds holding LGND
JT
CAM
UBS Group's LGND Position: Q2 2026 in Review
UBS Group increased its Ligand Pharmaceuticals (LGND) stake by 19% in Q2 2026, buying an estimated $4.73M and bringing the position to 124,674 shares worth $39.4M. The position accounts for 0.01% of the portfolio, ranked #1986.
UBS Group first reported a position in LGND in Q4 2014 and has held it in 47 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- UBS Group held 124,674 shares of Ligand Pharmaceuticals worth $39.4M as of Q2 2026.
- UBS Group bought 20,094 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.73M.
- Ligand Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q2 2026, its #1986 holding.
- UBS Group first reported a position in Ligand Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.